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Objective. In patients with type 2 diabetes (T2D) and critical limb ischemia (CLI), migration of 
circulating CD34+ cells predicted cardiovascular mortality at 18 months post-revascularization. 
This study aimed to provide long-term validation and mechanistic understanding of the 
biomarker.  
Research Design and Methods. The association between CD34+ cell migration and 
cardiovascular mortality was reassessed at 6 years post-revascularization. In a new series of 
T2D-CLI and control subjects, immuno-sorted bone marrow (BM)-CD34+ cells were profiled for 
microRNA expression and assessed for apoptosis and angiogenesis activity. The differentially 
regulated microRNA-21, and its pro-apoptotic target PDCD4, were titrated to verify their 
contribution in transferring damaging signals from CD34+ cells to endothelial cells. 
Results. Multivariable regression analysis confirmed CD34+ cell migration forecasts long-term 
cardiovascular mortality. CD34+ cells from T2D-CLI patients were more apoptotic and less 
proangiogenic than controls and featured microRNA-21 downregulation, modulation of several 
long non-coding RNAs acting as microRNA-21 sponges, and upregulation of the microRNA-21 
proapoptotic target PDCD4. Silencing miR-21 in control CD34+ cells phenocopied the T2D-CLI 
cell behavior. In coculture, T2D-CLI CD34+ cells imprinted naïve endothelial cells, increasing 
apoptosis, reducing network formation, and modulating the TUG1 sponge/microRNA-
21/PDCD4 axis.  Silencing PDCD4 or scavenging ROS protected endothelial cells from the 
negative influence of T2D-CLI CD34+ cells 
Conclusions. Migration of CD34+ cells predicts long-term cardiovascular mortality in T2D-CLI 
patients. An altered paracrine signalling conveys anti-angiogenic and pro-apoptotic features 








The chemokine stromal-derived factor-1 (SDF-1) participates in cardiovascular repair through 
the mobilization of bone marrow (BM)-derived CD34+ progenitor cells that express the CXCR4 
receptor. CD34+CXCR4+ cells positively interact with vascular endothelium by releasing trophic 
soluble factors and extracellular vesicles (EVs).  Risk factors, ageing, and age-related diseases 
compromise this homeostatic mechanism by perturbing the BM microenvironment1, 2. 
Interestingly, both biased myelopoiesis and deficit/dysfunction of CD34+ cells are associated 
with an increased risk of cardiovascular morbidity and mortality3-10.  
We showed that CD34+ cell migration predicted cardiovascular mortality in patients with 
type 2 diabetes (T2D) undergoing revascularization of critical limb ischemia (CLI) 10.  
Phenotypic changes in CD34+ cells may cause systemic vascular damage in these high-risk 
patients through anti-angiogenic and pro-apoptotic  microRNAs (miRs)10-13.  
The present study investigated (1) if CD34+ cells predict cardiovascular mortality long-






See Supplementary Data online for supplemental Tables and Figures  
Study 1: CD34+ cell migration predicts long-term mortality 
We performed a phone survey of T2D-CLI patients recruited in the NCT01269580 study, which 
demonstrated that migration of peripheral blood (PB) CD45dimCD34+CXCR4+KDR+ cells 
predicted cardiovascular death after angioplasty10. At 6 years,15 patients were lost to follow-
up and therefore excluded. Baseline characteristics of the remaining 104 patients are 
summarized in Supplemental Table 1.  
Study 2: Molecular mediators of CD34+ cell-induced vascular damage 
Clinical characteristics of a new cohort, comprising 47 controls and 41 patients with T2D, of 
which 30 affected by CLI, are reported in Supplemental Table 2. T2D and CLI were defined 
according to the American Diabetes Association and TASC 2007, respectively. Exclusion 
criteria: acute disease/infection, immune diseases, current/past hematological disorders or 
malignancy, unstable angina, recent (within 6 months) myocardial infarction or stroke, liver 
failure, renal failure, and pregnancy. All participants signed an informed consent to donate the 
BM leftovers from femoral head otherwise discarded during hip replacement surgery (ctr and 
subjects with T2D without complications) or BM aspirates of the iliac crest performed ad hoc 
for the study (T2D-CLI patients).  
The studies received ethical authorization from the IRCCS MultiMedica, Milan, Italy 
(PROT 20/2010), Bristol University, Bristol, UK (REC14/SW/1083 and REC14/WA/1005), and 
Santa Maria ‘Ca Foncello Hospital, Treviso, Italy (DDG 2333/2017)13, 14. BM-CD34+ cells were 
assessed in situ or following immunomagnetic beads isolation as described in 13. Some assays 
were conducted using the CD34+ cells-derived conditioned medium (CCM) and respective EVs 






MicroRNAs and gene expression analyses of CD34+ cells 
MiR profiling was conducted at Exiqon Services, Denmark. Total RNA (30ng) was reverse-
transcribed using the miRCURY LNA™ Universal RT miR PCR, Polyadenylation and cDNA 
synthesis kit (Exiqon). The amplification was performed in a LightCycler® 480 Real-Time PCR 
System (Roche) in 384 well plates. A total number of 372 miRs were tested. A cut-off (Ct>37) 
was used to consider a miR as expressed and included in the subsequent analyses.  
For biological validation and expressional studies, RNA was extracted from cultured 
cells, cell-derived CCM/EVs, plasma, and plasma-derived EVs using miRNeasy Mini Kit 
(Qiagen) following the manufacturer’s instructions. Quantitative RT-PCR was performed with 
the QuantStudio 6 Flex Real-Time PCR using miR TaqMan probes (Thermo Fisher) and 
lncRNA/gene primers listed in Supplemental Table 3. MiR-21 was silenced in CTRL-BM-
CD34+cells by transfecting them with 50nmol/L anti-miR-21-5p (AM10206Ambion) while 
controls were transfected with a non-targeting sequence or scramble (SCR) (AM4611, 
Silencer® Negative Control, Ambion), employing transfection reagents (Genlantis) according 
to the manufacturer’s protocol. 
In vitro migration and flow cytometry 
PB-MNCs in vitro migration assays using SDF-1 as chemoattractant were performed using 
transwell chambers as described10. Migrated cells were stained for surface antigens CD45 
(FITC, BD Bioscience), CD34 (PeCy7, BD Bioscience), CXCR4 (APC, BD Bioscience), then 
fixed in Met-OH, permeabilized in PBS-Tween 0.1%-BSA 0.5% and stained for intracellular 
antigen PDCD4 (Abcam) with secondary antibody anti-rabbit-PE (BD Bioscience). Cells were 
analyzed using a FACSCanto flow cytometer with the FACSDiva software (both from BD 
Biosciences) 
Apoptosis assay 
BM-CD34+ cells or HUVECs were stained with 7-AAD/Annexin-V and analyzed on FACSCanto 




cells. Caspase-3/7 Assay (Promega) was performed on HUVECs exposed to CD34+ cells 
CCMs.  
PDCD4 silencing 
HUVECs were transfected with 50 nmol/L siPDCD4 (Dharmacon) or non-targeting sequence, 
(AM4611, Silencer Negative Control, Ambion). 
Immunohistochemistry  
Paraffin embedded-BM sections were incubated with: rabbit anti-PDCD4 (1:200; abcam), 
mouse anti CD34 (1:5, Dako), rabbit anti 4-Hydroxy-2-Nonenal (4-HNE) (1:500, Bioss). Nuclei 
were counterstained with DAPI (1 μg/mL, Sigma Aldrich). Images were acquired with a 
fluorescent microscope (Leica microsystem DM6 B) at 63X magnification and analyzed using 
Fiji software. Cultured HUVECs were fixed with 4% PFA (Electron Microscopy Science), 
permeabilized with 0.3% triton (Sigma Aldrich), and stained with rabbit anti-PDCD4 (1:200). 
Nuclei were counterstained with DAPI (1μg/mL, Sigma Aldrich). Microphotographs were 
captured using a Zeiss microscope equipped with digital image processing software 
(AxioVision Imaging System). 
Immunoistochemistry: BM sections were stained with rabbit anti-PDCD4 (1:200) by 
BenchMark ULTRA system (Roche). Ten images for each sample were acquired with an optical 
microscope (Nikon Eclipse E800) at 40X magnification and quantified by using ImageJ 
software. 
In vitro angiogenesis 
BM-CD34+ cells, their CCM, or isolated EVs were cocultured with HUVECs (1:1 ratio) on 
Matrigel™ (Corning® Incorporated Life Sciences)15. 
Statistical analyses  
Continuous variables were expressed as mean ± standard deviation or standard error as 
indicated, tested for normality by the Kolmogorov-Smirnov test, and compared using 




appropriate. Categorical variables were expressed as frequency and percentage, and 
compared by Chi-Square test or Fisher’s Exact test. A p-value < 0.05 was considered 
statistically significant. SAS (version 9.4), R (version 3.4.4), and GraphPad Prism (version 7) 
were used for analyses and graphics. 
In study 1, cumulative incidences of events were drawn overall and for data stratified by 
cells (above vs. below the median) that significantly differed between participants with or 
without events. This analysis considered the competitive causes of the event;16 specifically, in 
the case of cardiovascular death, other-causes-of-death were considered as a competitive 
event, and vice-versa. Comparisons between incidence curves were assessed fitting the 
'proportional sub-distribution hazards' regression model17. Time-to-event was defined as the 
time from revascularization to death (cardiovascular or for other causes). Patients lost to follow-
up were excluded from the analyses. The 15th day of a given month and the month of June 
were imputed if the day or month of follow-up were missing, respectively. Incidence rate and 
95% Confidence Interval (CI) at 3 years and 6 years of follow-up were calculated for 
cardiovascular death and other-causes-of-death. 
To evaluate the association between basal cell counts and migratory activity and risk of 
death, the event-specific hazard ratio (HR) and 95% CI was calculated. HRs associated with 
cell migration were evaluated for one-year increase, for presence of history of coronary artery 
disease, and for 0.01 unit increase in the percentage of CD45dimCD34+CXCR4+KDR+ migrated 
cells toward SDF-1 over total MNCs. All models were performed for presence of investigated 
variable, if dichotomous, and for 1-unit increase of continuous variables, if not otherwise 
specified. A multivariable regression model was subsequently implemented, adjusting for 








CD34+ cell migration and cardiovascular mortality  
Supplemental Table 1 illustrates clinical/laboratory data of the 104 T2D-CLI patients who 
completed the 6-year follow-up.  
Three outcomes were considered: no-event (N=54), cardiovascular death (N=32), and 
other-causes-of-death (N=18). Age at recruitment was the only clinical data that differed among 
the 3 outcomes (p=0.0067) (Supplemental Table 4). Regarding CD45dimCD34+CXCR4+KDR+ 
cells, migration toward SDF-1 (experimental setting illustrated in Figure 1Ai) was higher in the 
cardiovascular death group compared with no-event or other-causes-of-death groups 
(p=0.0312), whereas there was no difference in PB levels of CD45dimCD34+CXCR4+KDR+ cells 
or in the migration of total MNCs and CD45dimCD34+CXCR4+KDR+ cells exposed to the SDF-
1 vehicle (Supplemental Table 5 and Supplemental Figure 1). 
As shown in Figure 1Aii and Supplemental Table 6, patients with values of SDF-1-
migrated cells ≥ the median had higher cumulative incidence of cardiovascular death compared 
with those with values < median (p=0.0012). Cell migration was associated with an increased 
cardiovascular risk (HR; 95%CI=1.10; 1.04-1.17. p = 0.0005, data not shown), further 
confirmed by multivariable Cox analysis simultaneously assessing the effect of age and 
prevalence of coronary artery disease (Supplemental Table 7).  
BM-CD34+ cell viability and angiogenic activity 
To obtain mechanistic insights into the observed association, we studied the functional 
characteristics of BM-CD34+ cells from a new series of patients with T2D or T2D-CLI and non-
diabetic subjects (controls). 
In line with previous studies13, flow cytometry analyses demonstrated that CD34+ cells 
immune-magnetically sorted from the BM of T2D-CLI patients have a 2.5-fold higher 




Moreover, using an in-vitro Matrigel assay, we demonstrated that the coculture of human 
umbilical vascular endothelial cells (HUVECs) with T2D-CLI BM-CD34+cells resulted in a lower 
number of branches compared with the coculture of HUVECs and control BM-CD34+ cells 
(Figure 1C). A marked decrease in endothelial network formation was also observed when 
incubating HUVECs with T2D-CLI BM-CD34+ cell-derived CCM or EVs (Figure 1C). These 
data demonstrate that BM-CD34+ cells from T2D-CLI patients have reduced viability and can 
transfer destabilizing signals to endothelial cells through factors secreted as soluble molecules 
or packaged in EVs.  
MiR signature in BM-CD34+ cells 
Diabetes influences the expression of several miRs in hematopoietic cells.11-13 An unbiased 
miR profiling of CD34+ cells isolated from the BM of controls (N=6) and T2D patients with (N=6) 
or without CLI (N=7) identified a suppressive effect of T2D on the quantity of expressed miRs 
(Supplemental Figure 2A&B), which might be attributable to the downregulation of Dicer 
(Supplemental Figure 2C&D), an endoribonuclease involved in miRNA maturation, as also 
described by others18. 
Supplemental Table 8 shows that 56 miRs were commonly expressed in the three 
groups. Moreover, two sets of 11 different miRs were shared by controls and T2D-CLI patients 
or controls and T2D, respectively. Of those not shared, 49 were unique to controls and 1, 
namely miR-146a, to T2D-CLI, whereas none was exclusive to T2D. As shown in 
Supplemental Table 9, 18 miRs were differentially expressed in cells from T2D subjects, with 
or without CLI, compared with controls, with two of them, miR-21 and miR-30e, being shared 
by the two T2D groups. The heatmap diagram in Figure 2A indicates a marked separation of 
miR expression in T2D-CLI compared with controls, while T2D values were spread between 
controls and T2D-CLI. Among the miRs that showed a differential expression between T2D-
CLI and controls, we studied a set of 6 miRs (miR-125a, miR-222, let-7e, miR-93, miR-21, and 




(Supplemental Table 10). To validate the profiling results, we performed single PCR analyses 
for the 6 miRs of interest on BM-CD34+ cells isolated from a new set of donors (controls, N=5; 
T2D, N=4; T2D-CLI, N=4) using an Applied Biosystem platform and normalizing miR 
expression to U6snoRNA, which showed a stable expression among the 3 groups. Three miRs 
from the set of choice, miR-125a, miR-21, and miR-30e, were significantly modulated in the 
new cohort (Figure 2B).  
Downregulation of miR-21 associated with reciprocal changes in its target PDCD4 
MiR-21, one of the most highly expressed miRs in mammalian cells, is modulated in 
cardiovascular disease.19-23 However, little is known regarding the expression of miR-21 in 
hematopoietic progenitor cells. Data of RT-PCR confirmed the downregulation of mature miR-
21 in sorted T2D-CLI BM-CD34+ cells (Figure 2Ci), whereas the levels of the corresponding 
pri-miR were similar to controls (data not shown).  MiR-21 was also found in CD34+ cell-derived 
CCMs and EVs, but no difference was seen when comparing T2D-CLI patients and controls 
(Figure 2Ci). Interestingly, miR-21 levels were decreased in plasma and EVs isolated from the 
PB of T2D-CLI patients (Figure 2 Cii). 
Long ncRNAs can act as miR sponges, thereby interfering with regulation of miR targets. 
We investigated the expression of several long ncRNAs reportedly implicated miR-21 
modulation 24-28. As shown in Figure 2Ci, TALNEC2 was upregulated in T2D-CLI BM-CD34+ 
cells and respective CCM; TUG1 was decreased in cells and increased in the CCM; MEG3 
was not altered; and TCONS was downregulated in CCM. These data suggest that TALNEC2 
could inhibit miR-21 at intracellular level, and, together with TUG1, at extracellular level. 
Moreover, all the studied sponges were upregulated either in plasma, EVs, or both, suggesting 
they may synergize in inhibiting miR-21 in the circulation (Figure 2Cii). 
The pro-apoptotic factor PDCD4 is a validated target of miR-21 19. In line with the miR-21 
downregulation, we found higher PDCD4 mRNA levels in T2D-CLI BM-CD34+ cells (Figure 




BM (Figure 2E). Altogether, these data point at a novel molecular mechanism involving the 
downregulation of miR-21 and induction of PDCD4 in T2D-CLI CD34+ cells. 
Migration toward SDF-1 enriches a population of CD34+/CXCR+/PDCD4+ cells 
CD34+CXCR4+ cells represented a small fraction (1.5±0.2%) of the total CD34+ cell population 
in PB of T2D-CLI patients. PDCD4 was more abundant in the CD34+CXCR4+ (77.9±0.4%) than 
in the CD34+CXCR4- cell fraction (5.8±0.2%). Moreover, SDF-1-stimulated migration of PB-
MNCs resulted in an enrichment of cells expressing both CXCR4 and PDCD4 in the migrated 
fraction (Supplemental Figure 3).  
Silencing miR-21 in control BM-CD34+ cells recapitulates the negative features of T2D-
CLI CD34+ cells 
Next, we sought confirmation of a direct link between T2D-CLI-associated miR-21 
downregulation and BM-CD34+ cell dysfunction. To this aim, we silenced miR-21 in control BM-
CD34+ cells using an anti-miR strategy. The effective miR-21 knock-down (Figure 3A) was 
associated with PDCD4 upregulation (Figure 3B), and increased apoptotic events compared 
with SCR-treated cells (Figure 3C). Moreover, miR-21 silencing conferred anti-angiogenic 
properties to CD34+ cells as well as to the CD34+ cell-derived CCM and EVs (Figure 3D).   
Transfer of pro-apoptotic miR-21/PDCD4 signaling to endothelial cells  
We next assessed if the negative crosstalk between CD34+ cells and endothelial cells involves 
the direct transfer of miR-21 or PDCD4 or is mediated by associated factors. To this purpose, 
using a protocol illustrated in Figure 3E, we measured the relative expression of miR-21 and 
PDCD4 in HUVECs exposed to the CCM from control CD34+ cells (either naïve or transfected 
with anti-miR-21 or SCR) or to the CCM from T2D-CLI CD34+ cells. Interestingly, plotting the 
expressional values of miR-21 and PDCD4 from the 4 groups demonstrated an inverse 
relationship between the miR and its target (Figure 3E). This indicates that modulation of the 
miR-21/PDCD4 duo in BM-CD34+ cells can induce similar expressional changes in the 




demonstrated that PDCD4 silencing in HUVECs remarkably reduced the apoptosis caused by 
the exposure to the CCM from T2D-CLI CD34+ cells (Figure 3F). A dedicated ELISA could not 
detect PDCD4 in the CD34+ cells-derived CCM. This data suggests that CD34+ cells induce 
apoptosis in HUVECs through different paracrine mechanisms.  
Implication of TUG1 and oxidative stress  
The presence of miR-21 sponges in the CCM from T2D-CLI CD34+ cells suggested they could 
act paracrinally to inhibit miR-21 in endothelial cells. Therefore, we assessed TALNEC2, 
TUG1, MEG3, and TCONS in HUVECs either naïve or exposed to the CCM from control or 
T2D-CLI CD34+ cells. Results confirmed the downregulation of miR-21 and the induction of 
PDCD4 by the T2D-CLI CCM and demonstrated TUG1 was the only upregulated long ncRNA 
in conditioned HUVECs (Figure 4A).   
Reciprocal interactions exist between long ncRNAs, and ROS production and 
scavenging29. Relevant to our study, H2O2 and hypoxia reportedly induced TUG1 in 
cardiomyocytes, thereby increasing ROS production and apoptosis30. Hence, we hypothesized 
that oxidative stress could be involved in the transfer of pro-apoptotic signaling to endothelial 
cells. This was confirmed by multiple evidences: (1) T2-CLI BM-CD34+ cells showed elevated 
in situ 4-HNE staining, a marker of oxidative damage and lipid peroxidation (Figure 4B), (2) 
treatment of HUVECs with increasing H2O2 concentrations induced miR-21 inhibition and 
PDCD4 upregulation (Figure 4C), and (3) ROS scavenging with N-acetylcysteine (NAC) 
blocked the miR-21 downregulation in HUVECs exposed to the CCM from T2D-CLI CD34+ 
cells (Figure 4Di) or to the CCM from anti-miR-21-transfected control CD34+ cells (Figure 
4Dii). In parallel, NAC abrogated the induction of PDCD4 by the CCMs (Figure 4Diii and 
Figure 4Div). It also counteracted the apoptosis of HUVECs exposed to the CCM from T2D-
CLI CD34+ cells (Figure 4Ei) but was unable to prevent the apoptosis of HUVECs exposed to 
the CCM from miR-21-silenced CD34+ cells (Figure 4Eii). These findings indicate that ROS in 




balance from T2D-CLI CD34+ cells to endothelial cells (Figure 4F). They also point to the 
possibility that the total disruption of miR-21 impacts on additional pro-apoptotic inducers that 






In an extended follow-up of T2D-CLI, CD34+ cell migration maintained a predictive value at 6 
years post-angioplasty. In these critical patients, CD34 cells responsive to SDF-1 
chemoattraction exert negative effects on the vascular endothelium through a mechanism 
involving miR-21 inhibition and PDCD4 upregulation.  
In the high-migratory group, cardiovascular mortality accrued during the first years of 
follow-up, with the difference vs. the low-migratory group remaining unchanged later. Most 
patients with the highest cardiovascular risk had already died at that stage, resulting in a 
reduction of the target for prediction. Moreover, mortality for other causes can act as a strong 
opposer in an elderly population. Nonetheless, the biomarker maintained its validity in a 
multivariable analysis accounting for the age of participants.  
Reduction and dysfunction of stem/progenitor cells is associated with and predicts adverse 
outcomes of diabetic complications.8 Thus, at first glance, our data appear counterintuitive. We 
hypothesized that sub-fractions of BM-CD34+ cells could become anti-angiogenic and pro-
apoptotic due to the adverse metabolic milieu they are exposed to in the BM and circulation. 
Once entered in the circulation, these cells may convey pathogenic signals to the vascular 
endothelium, thereby accelerating ischemic complications. 
 Accumulating evidence indicates that CLI aggravates the remodeling effect of T2D on 
the BM niche and induces a senescent phenotype in CD34+ cells, which may be, at least in 
part, attributable to alteration in miR biogenesis, expression, and degradation13, 18. The 
observed reduction of expressed miRs in T2D BM-CD34+ cells may be attributable to a block 
in the miR processing, as suggested by Dicer downregulation. Among differentially expressed 
miRs, we focused on miR-21, because of its involvement in cardiovascular disease 31-34 MiR-
21 downregulation in T2D-CLI CD34+ cells was associated with upregulation of the 
programmed cell death protein PDCD4, a validated inhibitory target of miR-21, and with 




the same phenotype in CD34+ cells of subjects without diabetes. Moreover, data of an SDF-1 
migration assay on T2D-CLI PB-MNCs demonstrated the high co-expression of PDCD4 and 
CXCR4 within the migrated CD34+ cell fraction. This finding provides a key of interpretation for 
the link between CD34+CXCR4+ cell migration and cardiovascular death in the follow-up study 
on T2D-CLI patients.  
 MiR‐21 is the most abundant miRNA in macrophages and its downregulation has been 
associated with induction of atherosclerosis, plaque necrosis, and vascular inflammation 35. 
Silencing of miR‐21 in macrophages increases the expression of mitogen‐activated protein 
kinase kinase 3, thereby leading to the activation of the p38‐CHOP and cJNK signaling 
pathways and triggering macrophage apoptosis 35. Additionally, miR‐21-silenced macrophages 
are unable to remove apoptotic cells, which contributes in delaying the resolution of 
inflammation35. The miR-21 inhibitory target PDCD4 acts as a tumor suppressor protein 
involved in programmed cell death. Recent cardiovascular research has shown that PDCD4 is 
upregulated in coronary arteries of atherosclerotic rats, where it participates in the formation of 
coronary plaques, through destabilization of vascular smooth muscle cells and promotion of 
inflammatory chemokines 36. Nonetheless, the regulation of miR-21/PDCD4 interaction is only 
partially known. Prostaglandins reportedly act as inducers of miR-21 expression and 
suppressors of PDCD4 protein; whereas, cyclooxygenase 2 inhibitors produce opposite 
effects37. Moreover, several long ncRNAs can act as sponges for miR-21.24-28 For instance, 
miR-21 is a direct target of MEG3, and, in hypoxic vascular cells, MEG3 interferes with miR-
21 modulation of PTEN resulting in cell proliferation and migration.27 Likewise, studies on H9c2 
cells showed that TALNEC2 modulates miR-21/PDCD4expression under hypoxia, aggravating 
its consequences.25 TCONS is an endothelium-associated long ncRNA involved in plaque 
progression. Binding of miR-21 to TCONS reduces its expression and, for this reason, was 
proposed as potential treatment to improve endothelial dysfunction and plaque stabilization 28. 




Both oxidative stress and ischemia induce the sponging activity of TUG1, thereby stimulating 
intracellular ROS accumulation, and aggravating the ischemic injury30. Interestingly, we found 
that the above long ncRNAs were modulated in CD34+ cells and PB of T2D-CLI patients. 
Moreover, exposure of HUVECs to the CCM of T2D-CLI CD34+ cells induced the expression 
of TUG1 and PDCD4, while suppressing miR-21. This mechanism may be ROS dependent 
when considering that the inhibition exerted by NAC resulted in improved cell survival. We 
propose that CD34+ cells recruited from PB may exert a sponge-dependent inhibition of the 
interaction between miR-21 and PDCD4, thereby sustaining vascular damage.  Elevated PB 
levels of miR-21 sponges could strengthen this cellular crosstalk. 
These findings have clinical and therapeutic implications, but also raise new questions. 
Currently, long-term prognosis of CLI is based on clinical parameters39. Our study suggests 
that the assessment of CD34+ cells profile may help identify high-risk patients for whom more 
aggressive treatments are necessary. Although more sophisticated than traditional biomarkers, 
cellular biomarkers can be very useful in helping us understand the complex interplay among 
cellular systems in inducing diabetic vascular disease. In this respect, circulating cells offer a 
more feasible means for molecular profiling than BM cells, also considering the variability in 
cell composition of different BM sites. This last aspect represents a limitation of our study, as 
BM samples were obtained from the femoral head or iliac crest aspirates with the intention of 
not interfering with clinical practice and patients’ care.  
PDCD4 might represent a valuable biomarker and therapeutic target in ischemic disease. 
The latter assumption is indirectly supported by the established benefit of prostaglandin E1, an 
inhibitor of PDCD4, in the treatment of limb ischemia. Novel treatments targeting upstream 
modulators of PDCD4, including miR-21 and related sponges, might be also considered for 
treatment of CLI. Finally, autologous BM-CD34+ cells are currently used in clinical trials of CLI 
patients. Our study calls for caution in using CD34+ cells that carry a proapoptotic and 




to determine if this signature can be exploited to increase the safety and efficacy of the cell 
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Figure 1. Migration of CD34
+
 cells toward SDF-1 predicts cardiovascular mortality and 
is associated with reduced cell viability and angiogenic capacity. A) Left, schematic view 
of the in vitro migration assay; right, cumulative incidence of mortality for cardiovascular causes 









 migrated toward SDF-1. Red line represents the incidence in 
the group with migration value below the median value, while the blue line indicates the 
cumulative incidence in the group with migration value equal or above the median. P-value for 
the difference between the two curves =0.0012. B) Typical flow cytometry displacement curves 
and bar graph showing the percent of bone marrow (BM)-derived CD34
+
 cells expressing 
AnnexinV in controls (ctr) and patients with type 2 diabetes with critical limb ischemia (T2D-
CLI) (N=3 in each group). D) Representative microscopy images of the Matrigel assay (bar = 
50μm) and bar graphs showing fold changes in the average number of network branches made 
by human umbilical vein endothelial cells (HUVECs) in the presence or the absence of CD34+ 
cells (coculture 1:1), CD34+ cell-derived conditioned medium (CCM), or CD34+ cell-derived 
extracellular vesiscles (EVs) from controls (empty bars, N=5) or patients with T2D-CLI (black 
bars, N=4). Values are means ± SE; *p<0.05 vs. ctr. 
 
Figure 2. MicroRNA profiling of bone marrow-derived CD34+ cells unveils the modulation 
of microRNA-21 and its target PDCD4 in patients with type 2 diabetes and critical limb 
ischemia. A) Heat map showing that bone marrow (BM)-CD34+ cells isolated from subjects 
with type 2 diabetes either uncomplicated (T2D) or complicated by critical limb ischemia (T2D-
CLI) bear a specific microRNA (miR) profile. Quantitative RT-PCR data, N=6 donor/group.  B) 
Bar graph showing the average relative expression of a group of 6 miRs assessed in a 




(ctr: N=5, with T2D: N=4, with T2D-CLI N=4). Quantitative RT-PCR. *p<0.05 vs. ctr, #p<0.05 
vs. with T2D. C) (i) Relative expression of mature miR-21 and miR-21 sponges in BM-derived 
CD34+  cells (N=4), CD34+ cell-derived conditioned medium (CCM) (ctr: N=8, T2D-CLI: N=7) 
and isolated extracellular vesicles (EVs) (ctr: N=8, T2D-CLI: N=7) from new donors. (ii) Relative 
expression of mature miR-21 and miR-21 sponges in plasma (N=9-10) and EVs (N=4-5). 
Quantitative RT-PCR. *p<0.05, *p<0.01, and ***p<0.001 vs. ctr. D) PDCD4 mRNA modulation 
in T2D-CLI BM-CD34+ cells. Quantitative RT-PCR (N=8) *p<0.05 vs. ctr. E) (i) Bar graph show 
the frequency of PDCD4 positive cells over total number of hematoxylin positive nuclei in the 
BM of ctr and T2D-CLI subjects (N=3) *p<0.05 vs. ctr. (ii and iii) Representative 
microphotographs of BM using immunohistochemistry (upper images, scale bar 20µm), and 
immunofluorescent microscopy (lower images, scale bar 10µm). White arrowheads point at 
CD34+ cells.  
 
Figure 3. Inhibition of miR-21 in BM-CD34+ cells from control subjects mimics diabetes-
associated dysfunction. Silencing miR-21 in CD34+ cells resulted in A) miR-21 reduction (RT-
PCR, N=3) and B) PDCD4 upregulation (RT-PCR, N=6). *p<0.05 vs. scramble (SCR). C) miR-
21 inhibition is associated with increased apoptosis of BM-CD34+ cells, bar graph of Annexin 
V+/7AAD- cells assessed using flow cytometry. (N=7). D) Anti-angiogenic action of miR-21-
silenced BM-CD34+ cells (N=4), cell-derived conditioned medium (CCM, N=3) and extracellular 
vesicles (EVs, N=3). Human umbilcal vein endothelial cells (HUVECs) networking analysis on 
Matrigel. Scale bar 50µm. E) Left, schematic view of the experimental setting; right, negative 
correlation between PDCD4 and miR-21 in HUVECs treated with the CCM from CD34+ cells. 
The graph reports data of average PDCD4 protein levels (as percentage of positive HUVECs 
identified using immunofluorescence microscopy) and average miR-21 expressional levels (by 
PCR analysis). Colored circles indicate the source of CCMs. F) Upper panel, scheme of the 




either SCR- or siPDCD4 transfected after treatment with CD34+-CCM. Flow cytometry 
analysis, N=3 donors/condition.  
 
Figure 4. Exposure of endothelial cells to the conditioned medium of  CD34+ cells from 
patients with type 2 diabetes and critical limb ischemia induces a modulation of the miR-
21/PDCD4 axis through a mechanism involving reactive oxygen species and the miR-21 
sponge TUG1. A) Bar graph showing the average relative expression of miR-21, PDCD4, and 
indicated long ncRNA in human umbilical vein endothelial cells (HUVECs) either not treated 
(NT) or treated with the conditioned media (CCM) from bone marrow (BM)-derived CD34+ cells 
of controls (ctr) or type 2 diabetes+critical limb ischemia patients (T2D-CLI) (N=4 donors, 
*p<0.05 vs. ctr CCM. B) In situ detection of reactive oxygen species (ROS) levels assessed by 
measuring 4-Hydroxy-2-Nonenal (4-HNE) in BM-CD34+ cells. Representative images of 
immunofluorescence staining (IF) and bar graph of average data (ctr: N=5 and T2D-CLI: N=6) 
*p<0.05 . White arrowheads in IF microphotographs point at CD34+ cells.  Scale bar: 10µm. C) 
Bar graph showing the relative expression of miR-21 (i) and PDCD4 mRNA (ii) (RT-PCR, N=4) 
and PDCD4 protein (iii) (immunofluorescence staining, NT: N=3 and treated: N=5) in HUVECs 
exposed to H2O2 at the indicated concentrations. *p<0.05 vs. NT. D) Antioxidant action of N-
acetyl-L-cysteine (NAC) results in prevention of miR-21 inhibition in HUVECs that were 
exposed to the CCM of CD34+ cells from patients with T2D-CLI (i) or to the CCM of miR-21-
silenced CD34+ cells from ctr (ii). Bar graphs with average RT-PCR data show there was no 
difference with respective CCM from ctr CD34+ cells or CCM from ctr CD34+ cells transfected 
with scramble siRNA (SCR). (iii) Percentage of PDCD4 positive HUVECs exposed to the CCM 
of CD34+ cells from ctr or T2D-CLI patients with (+) or without (-) NAC; *p<0.05 as indicated 
by the lines. (iv) Percentage of PDCD4 positive HUVECs exposed to the CCM of ctr CD34+ 
cells, transfected with either SCR or anti-miR-21, with (+) or without (-) NAC; *p<0.05 and 




scavenging of ROS protects HUVECs from CD34-CCM-induced apotosis. Conditions in (i) and 
(ii) are the same of panel E (iii) and (iv), respectively. Bar graphs of average caspase 3/7 activity 
that was measured using ELISA; *p<0.05 and **p<0.01 as indicated by the lines (N=3). E) 
Diagram of propesed molecular interaction between CD34+ cell and endothelial cells, involving 
the participation of ROS and miR-21 sponge TUG1. Section of CD34+ cell on the left of dotted 
line shows the inhibition of proapoptotic PDCD4 by miR-21 leading to prosurvival signalling to 
the vascular endothelium. Section of CD34+ cell on the right illustrating the interference of miR-
21 sponge on the inhibitory target, which result in activation of pro-apoptotic signalling in 
vascular endothelium. 
 
 
